CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
about
Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV InfectionPharmacogenomics of breast cancer therapy: an updateIncreased expression of MyD88 and association with paclitaxel resistance in breast cancer.Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathyGenetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypesInfluence of Feature Encoding and Choice of Classifier on Disease Risk Prediction in Genome-Wide Association Studies.Actionable pharmacogenetic markers for prediction and prognosis in breast cancer.Informative gene network for chemotherapy-induced peripheral neuropathyGenome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease RecurrenceCYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelPolymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.Cancer pharmacogenomics: early promise, but concerted effort needed.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.Germline pharmacogenetics of paclitaxel for cancer treatment.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Pharmacogenetics and breast cancer management: current status and perspectives.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.Drug transporters in breast cancer: response to anthracyclines and taxanes.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Cancer predisposition syndromes: lessons for truly precision medicine.Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.Potential drug interaction between paclitaxel and clopidogrel.Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.Taxane-Induced Peripheral Neurotoxicity.Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.'Toxgnostics': an unmet need in cancer medicine
P2860
Q24289538-BADC7111-7580-4489-AF45-C2F1D67DACC7Q26749811-8440EBDA-8A15-43ED-AF39-B318F3A74BBBQ27006783-033224EE-78EE-4BF9-B5A5-94E403B169BCQ27853281-EA8FB522-7432-4B91-A841-EF78C4C3F599Q28943314-AF76A57C-F07B-40E1-9576-A91E43FC56C8Q33418358-62B29E04-C86D-4171-97C3-438B64B1B389Q34633385-132AAB87-B78D-4B25-A9DF-68A34D5AFD58Q35191233-3C6C14E0-72DF-4CE5-8918-D995956275A0Q35749062-C8F67FA8-EBBA-48E8-9442-CE7E070EFDEBQ35879741-78E03B68-E775-4D80-979F-D3ACF16035DFQ35945680-CE85175E-8BEF-41D7-89EC-BDE31B7748F0Q36475847-F587A8EE-4C86-4FE6-A2F5-FE5E0A0D236EQ36545157-694AD5DD-E1A2-4969-A5E4-5CA14D8BD8D7Q36712351-384B86FC-2E45-4B28-A9C4-57F2E757CFA5Q36862832-AB770071-1097-4556-834C-84D745923E05Q37187663-5EBFB405-D552-4222-A1F2-2DCC0BA8D1C3Q37233810-616A0624-09DD-45F5-9CDB-72C8CA822C2FQ37508335-4F8DC704-E47D-4B90-BBD9-015AD5B2171FQ37590883-D6B37EA9-A19C-43FC-B0BE-19599C2C4621Q37684533-56093240-F427-467E-A267-D07BBB50C77BQ37696110-B37290D2-5D5E-41FA-85CF-4A2F481DE6F8Q38120289-D733FD7D-A028-4E29-B702-433DFD790224Q38130410-B072846D-B725-4827-B3ED-7AAA4027DED9Q38358816-03030B7C-4174-4EA1-8C42-384F65234D11Q38414396-D08D7A57-1052-4605-8EC2-CF68AE293632Q38551666-0CEDD6EE-8E09-4EA3-BC63-48856B095567Q38575008-69D36883-8051-45CA-ABB9-764508C0168BQ38684505-82851108-8548-459F-A957-14E33D5B23D9Q39012229-034D089F-36B1-47CE-B509-3D0CEC9EFD11Q40793437-D272CA1E-D63B-4653-8415-BCF3174C9D51Q41227394-33E87B2F-71E4-4506-93DB-C5D7B8E05250Q42177423-75841E1B-E047-4E8F-A832-EB457EA15CCDQ43477148-EA2AFE6D-B71D-4EC1-9DC3-41560598CFC7Q45759415-DB9F5685-297C-4EE8-AF9D-C3C61D9758FCQ49784365-E667A250-DFF1-4A9F-B9BC-474677399BB4Q53078776-E325648E-3AC5-4925-AFD8-16A8E7F000A6Q56675475-84F45295-8522-414E-8D7B-536CF0849B6C
P2860
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 April 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CYP2C8*3 predicts benefit/risk ...... eiving neoadjuvant paclitaxel.
@en
CYP2C8*3 predicts benefit/risk ...... eiving neoadjuvant paclitaxel.
@nl
type
label
CYP2C8*3 predicts benefit/risk ...... eiving neoadjuvant paclitaxel.
@en
CYP2C8*3 predicts benefit/risk ...... eiving neoadjuvant paclitaxel.
@nl
prefLabel
CYP2C8*3 predicts benefit/risk ...... eiving neoadjuvant paclitaxel.
@en
CYP2C8*3 predicts benefit/risk ...... eiving neoadjuvant paclitaxel.
@nl
P2093
P2860
P1476
CYP2C8*3 predicts benefit/risk ...... eiving neoadjuvant paclitaxel.
@en
P2093
Alison A Motsinger-Reif
Amy Drobish
Daniel L Hertz
E Claire Dees
Howard L McLeod
Lisa A Carey
Stacey J Winham
P2860
P2888
P304
P356
10.1007/S10549-012-2054-0
P407
P577
2012-04-18T00:00:00Z